Rashmikant Mohile

Managing Director

There was a time when product claims were largely accepted at face value. A skincare cream promised visible radiance, a nutraceutical claimed to improve immunity, or a hair serum assured stronger, healthier hair and consumers rarely questioned the science behind those statements.

That landscape has changed dramatically. Today's consumers are more informed, regulators are more vigilant, and brands operate in an environment where every claim is expected to stand up to scientific scrutiny. This shift has quietly transformed the role of Contract Research Organizations (CROs).

Once viewed primarily as partners for pharmaceutical drug development, CROs today occupy a far more strategic position within the consumer healthcare ecosystem. For cosmetics, nutraceuticals, OTC products and wellness brands, clinical research is no longer simply about regulatory compliance; it has become the foundation upon which product credibility, consumer confidence and brand differentiation are built. It is within this evolving landscape that C.L.A.I.M.S. CRO has carved a distinct identity.

Established in 2008, the company made a conscious decision not to become another broad-spectrum CRO. Instead, it chose to specialize in one of the industry's most demanding disciplines - claim substantiation.

Focusing on skincare, haircare, nutraceuticals, dietary supplements, OTC products and consumer healthcare, C.L.A.I.M.S. CRO helps companies answer one fundamental question: Can this product scientifically prove what it promises? - That philosophy has shaped the company's journey ever since.

Every Product Claim Begins with a Scientific Question

For many organizations, clinical research begins after product development is complete. At C.L.A.I.M.S. CRO, it begins much earlier—with the claim itself. Drawing upon decades of experience in pharmaceutical R&D, manufacturing and FMCG product development, the company's leadership recognized that successful clinical research requires much more than executing protocols. It demands an understanding of formulations, ingredients, consumer expectations and regulatory requirements simultaneously.

“When sponsors approach C.L.A.I.M.S. CRO, they often arrive with innovative products and ambitious claims rather than well-defined study protocols. Instead of merely conducting the requested trial, the scientific team works backwards, designing clinical methodologies that align measurable endpoints with the specific claims a company intends to communicate”, speaks Rashmikant Mohile, Managing Director.

This consultative approach transforms the organiza­tion from a service provider into a scientific partner. Rath­er than validating products after the fact, the organization helps clients build evidence that is meaningful from both scientific and commercial perspectives.

Its integrated operating model reinforces this philosophy. Unlike many conventional CROs that coordinate studies through external sites, C.L.A.I.M.S. CRO executes end-to-end clinical trials through its own infrastructure, supported by in-house dermatologists, investigators and trained clinical teams. This enables greater scientific oversight, operational consistency and quality control throughout the research process.

Beyond Clinical Observation: Measuring What the Human Eye Cannot

Clinical research has traditionally depended on physician observations and expert assessments. While these remain indispensable, the organization believes that modern claim substantiation requires a far greater level of objectivity. The organization has therefore invested extensively in advanced non-invasive instrumentation capable of generating precise quantitative data.

In anti-ageing studies, for example, sophisticated instruments measure wrinkle depth, wrinkle length, pigmentation, skin texture and multiple physiological parameters with remarkable precision. These measurements provide objective evidence that complements dermatologist evaluations and participant feedback, creating a far more comprehensive understanding of product performance.

The significance of this approach extends beyond technology itself. Objective measurement produces statistically robust datasets that strengthen the scientific credibility of every study while enabling brands to substantiate increasingly sophisticated product claims.

Equally important is the discipline behind these measurements. Every instrument undergoes continuous calibration, validation and standardization under the supervision of a dedicated instrumentation manager, ensuring that scientific accuracy remains consistent across every clinical evaluation. In an industry where even minor variations can influence research outcomes, precision is not simply a technical requirement - it is a competitive advantage.

Where AI Supports—But Never Replaces—Scientific Judgement

Artificial intelligence is rapidly finding applications across clinical research, but C.L.A.I.M.S. CRO has adopted a measured approach to its integration. Rather than viewing AI as a replacement for scientific expertise, the organization uses it selectively where it delivers the greatest value.

During protocol development, AI assists researchers in translating innovative marketing claims into measurable clinical endpoints, enabling more structured and scientifically aligned study designs. Following study completion, AI contributes to organizing, interpreting and presenting research findings in a manner that improves clarity and consistency without compromising scientific integrity. Yet the company remains clear about the limits of technology.

Study design, clinical interpretation, ethical oversight and statistical reasoning continue to rely on experienced scientists, clinicians and investigators. Technology may accelerate processes and enhance efficiency, but scientific judgement remains firmly human.

This balanced philosophy reflects the company's broader approach to innovation—embracing digital tools where they strengthen research while ensuring that evidence continues to be guided by scientific expertise rather than algorithms alone.

Scientific Integrity Is Not Negotiable

Perhaps the strongest measure of a CRO is not how it han­dles successful studies, but how it responds when out­comes differ from client expectations. For C.L.A.I.M.S. CRO, scientific integrity has never been open to compromise. Ev­ery study is conducted in accordance with internationally recognized Good Clinical Practice (ICH-GCP) guidelines, reviewed by registered Ethics Committees and registered with the Clinical Trials Registry of India (CTRI).

Sponsors receive complete visibility into project timelines - from ethics approvals and volunteer recruitment to statistical analysis and final reporting and are encouraged to observe study execution within regulatory boundaries. However, the company's commitment extends beyond compliance.

As its leadership often emphasizes, a CRO can control the quality of a clinical trial, but it cannot ethically influence its outcome. There are occasions when a product does not deliver the expected clinical results. In such situations, the organization focuses on helping clients understand the data through rigorous statistical analysis and transparent scientific interpretation rather than attempting to reshape conclusions.

That willingness to let science speak for itself has become one of the organization's defining characteristics. In an era where evidence increasingly shapes consumer trust, scientific neutrality is perhaps the most valuable service a research partner can offer.

Building the Future of Evidence-Based Consumer Healthcare

The rapid growth of nutraceuticals, cosmeceuticals and consumer healthcare products continues to reshape the clinical research landscape. Simultaneously, evolving regulatory frameworks and the global transition away from animal testing are creating new opportunities for in-vitro methodologies, advanced instrumentation and more sophisticated claim substantiation protocols.

C.L.A.I.M.S. CRO is expanding alongside these changes.

"The company continues to strengthen its capabilities across consumer studies, in-vitro evaluations and multicentric clinical trials while exploring strategic collaborations with international CROs seeking scientifically credible partners in India. As global brands increasingly look towards India for specialized clinical research, C.L.A.I.M.S. CRO is well positioned to contribute to the next phase of evidence-driven product development”, highlights Rashmikant.

More importantly, the company remains committed to the philosophy that has guided it since 2008—that clinical research should not merely generate reports but create scientific confidence.

In today's marketplace, consumers may be attracted by innovation, and marketers may create compelling narratives. Yet lasting trust is built only when every promise is supported by evidence. By helping organizations transform product claims into scientifically validated outcomes, C.L.A.I.M.S. CRO is doing more than conducting clinical trials—it is reinforcing the credibility of an industry where science has become the strongest brand differentiator.